Satralizumab, previously known as SA-237 , represents a promising therapy for a form of multiple sclerosis and other autoimmune conditions . Latest studies have indicated encouraging results regarding its effectiveness in lessening relapses and condition progression . Specifically , Phase III st

Belimumab, known as LymphoStat β, represents a novel approach for inflammatory diseases, particularly SLE. This biologic inhibits B cell activating factor, a key protein involved in lymphocyte production and antibody formation. By reducing BAFF levels, LymphoStat β positively suppresses the immun